Ecolab Inc. logo

Ecolab Inc.

ECL

NYSEBasic MaterialsChemicals - Specialty

Previous close

$281.63

+$0.15 · +0.05%

Aug 21, 4:00 PM ET

ECL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

32

Expensive

Momentum

41

Neutral

Sentiment

72

Bullish

Risk resilience

74

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Ecolab Inc. provides water, hygiene, and infection prevention solutions and services in the United States and internationally. The company operates through four segments: Global Water, Global Institutional & Specialty, Global Pest Elimination, and Global Life Sciences. The Global Water segment offers water treatment and process applications, and cleaning and sanitizing solutions to manufacturing, food and beverage processing, transportation, chemical, primary metals and mining, power generation, global refining, petrochemical, pulp and paper industries. The Global Institutional & Specialty segment provides cleaning and sanitizing products to the foodservice, healthcare, hospitality, lodging, government, education and retail industries. The Global Pest Elimination segment provides pest elimination services to detect, prevent, and eliminate pests comprising rodents and insects in full-service and quick-service restaurants, food and beverage processors, hotels, grocery operations, and other commercial segments, including education, life sciences, and healthcare. The Global Life Sciences segment provides cleaning and contamination control solutions to pharmaceutical and personal care manufacturers. It offers its products under the Ecolab, Kay, Purolite, and Bioquell brand names. The company sells its products through field sales and corporate account personnel, distributors, and dealers. Ecolab Inc. was founded in 1923 and is headquartered in Saint Paul, Minnesota.

Industry
Chemicals - Specialty
Sector
Basic Materials
Headquarters
US
CEO
Christophe Beck
Listed since
Feb 21, 1973
Employees
48,000

Market position

Day range

Current $281.63

52-week range

Current $281.63

Open
$281.32
Previous close
$281.48
Volume
2.22M
1.43× average
Average volume
1.55M
Average daily volume
Market cap
79.26B USD
Beta
0.89
Market reference 1
50-day average
$276.08
+2.01% above average
200-day average
$271.58
+3.70% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
83.16B USD
P/E (TTM)
37.55×
P/B (TTM)
7.88×
P/S (TTM)
4.71×
EV / EBITDA
24.02×
Earnings yield
2.79%
Free cash flow yield
2.56%
Dividend yield
1.01%

Profitability & efficiency

Gross margin
44.11%
Operating margin
17.37%
Net margin
12.57%
Return on equity
21.24%
Return on assets
8.40%
Return on invested capital
11.95%

Financial health

Debt / equity
1.37×
Current ratio
1.08×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends48%33%19%4%Gross margin, FY2021: 41.01%Gross margin, FY2022: 38.20%Gross margin, FY2023: 40.32%Gross margin, FY2024: 43.47%Gross margin, FY2025: 44.51%Operating margin, FY2021: 13.23%Operating margin, FY2022: 11.34%Operating margin, FY2023: 14.10%Operating margin, FY2024: 16.60%Operating margin, FY2025: 18.11%Net margin, FY2021: 8.87%Net margin, FY2022: 7.69%Net margin, FY2023: 8.96%Net margin, FY2024: 13.42%Net margin, FY2025: 12.91%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 41.01%. Gross margin FY2022 38.20%. Gross margin FY2023 40.32%. Gross margin FY2024 43.47%. Gross margin FY2025 44.51%. Operating margin FY2021 13.23%. Operating margin FY2022 11.34%. Operating margin FY2023 14.10%. Operating margin FY2024 16.60%. Operating margin FY2025 18.11%. Net margin FY2021 8.87%. Net margin FY2022 7.69%. Net margin FY2023 8.96%. Net margin FY2024 13.42%. Net margin FY2025 12.91%.

Income trends

Revenue

16.08B USD+2.16%

Operating income

2.91B USD+11.49%

Net income

2.08B USD-1.74%
Income trends across reported periods17.58B USD11.58B USD5.59B USD−407.25M USDRevenue, FY2021: 12.73B USDRevenue, FY2022: 14.19B USDRevenue, FY2023: 15.32B USDRevenue, FY2024: 15.74B USDRevenue, FY2025: 16.08B USDOperating income, FY2021: 1.68B USDOperating income, FY2022: 1.61B USDOperating income, FY2023: 2.16B USDOperating income, FY2024: 2.61B USDOperating income, FY2025: 2.91B USDNet income, FY2021: 1.13B USDNet income, FY2022: 1.09B USDNet income, FY2023: 1.37B USDNet income, FY2024: 2.11B USDNet income, FY2025: 2.08B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 12.73B USD. Revenue FY2022 14.19B USD. Revenue FY2023 15.32B USD. Revenue FY2024 15.74B USD. Revenue FY2025 16.08B USD. Operating income FY2021 1.68B USD. Operating income FY2022 1.61B USD. Operating income FY2023 2.16B USD. Operating income FY2024 2.61B USD. Operating income FY2025 2.91B USD. Net income FY2021 1.13B USD. Net income FY2022 1.09B USD. Net income FY2023 1.37B USD. Net income FY2024 2.11B USD. Net income FY2025 2.08B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue16.08B USD15.74B USD15.32B USD14.19B USD12.73B USD
Cost of goods sold8.92B USD8.9B USD9.14B USD8.77B USD7.51B USD
Gross profit7.16B USD6.84B USD6.18B USD5.42B USD5.22B USD
Research and development207M USD192M USD190M USD186M USD
Selling, general, and administrative4.26B USD4.02B USD3.82B USD3.62B USD3.35B USD
Operating expenses4.25B USD4.23B USD4.02B USD3.81B USD3.54B USD
Interest income57.8M USD52.2M USD8.5M USD12.3M USD
Interest expense241.1M USD338.4M USD354.7M USD263.7M USD216.2M USD
Depreciation and amortization672.6M USD935.4M USD923.6M USD938.7M USD843.1M USD
Operating income2.91B USD2.61B USD2.16B USD1.61B USD1.68B USD
Net income2.08B USD2.11B USD1.37B USD1.09B USD1.13B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 1 miss, 5 met estimates
Average EPS surprise
+0.20%
11 comparable reports
Latest EPS result
2.09
Estimate 2.08 · Beat by 0.48%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.271.981.71.41Q1 '25MetQ2 '25MetQ3 '25MissQ4 '25MetQ1 '26BeatQ2 '26MetQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 11, 2025: actual 1.81, estimate 1.81, surprise 0.00%, Met estimate. Q2 2025, reported Apr 29, 2025: actual 1.5, estimate 1.5, surprise 0.00%, Met estimate. Q3 2025, reported Jul 29, 2025: actual 1.89, estimate 1.9, surprise -0.53%, Miss. Q4 2025, reported Oct 28, 2025: actual 2.07, estimate 2.07, surprise 0.00%, Met estimate. Q1 2026, reported Feb 10, 2026: actual 2.08, estimate 2.07, surprise +0.48%, Beat. Q2 2026, reported Apr 28, 2026: actual 1.7, estimate 1.7, surprise 0.00%, Met estimate. Q3 2026, reported Jul 28, 2026: actual 2.09, estimate 2.08, surprise +0.48%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 2.18, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates4.89B4.43B3.97B3.51BQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 11, 2025: actual 4.01B USD, estimate 3.99B USD, surprise +0.49%, Beat. Q2 2025, reported Apr 29, 2025: actual 3.7B USD, estimate 3.7B USD, surprise -0.02%, Miss. Q3 2025, reported Jul 29, 2025: actual 4.03B USD, estimate 4.02B USD, surprise +0.12%, Beat. Q4 2025, reported Oct 28, 2025: actual 4.17B USD, estimate 4.12B USD, surprise +1.07%, Beat. Q1 2026, reported Feb 10, 2026: actual 4.19B USD, estimate 4.19B USD, surprise +0.05%, Beat. Q2 2026, reported Apr 28, 2026: actual 4.07B USD, estimate 4.03B USD, surprise +0.99%, Beat. Q3 2026, reported Jul 28, 2026: actual 4.42B USD, estimate 4.38B USD, surprise +0.75%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 4.7B USD, surprise —, Comparison unavailable.

ECL peers

ETFs holding ECL

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ECL

research.disclaimer